Member Info for AquaeSulis01

Paul, double bottom or triple chins have never been more irrelevant here. Basically, the assay results from Creswick once released will make or break this company in the short term and nothing else matters. Selling because you fear it might fall by 0.4p is not an option if you want to be in when the Creswick RNS drops

Shop now open

https://axisbiotix.com/collections/products

Adastra, will you re-post your previous BB comment when the company "smashes" through the 1300 barrier again?

The sensitive bit as I understand it, is that pre-registration does not equal firm orders. Consequently, the moment the company meets the actual initial constrained orders it has a confirmed initial launch number which in theory could be released tomorrow; not saying it will of course

I suspect the Board elected to release partial results from Cherry Tree because it was obviously not looking like a commercial proposition so no point in waiting fr the final drill completion. Creswick where at least two drill holes were completed awaiting assay results a month before Cherry Tree ,so are obviously available, is a different kettle of fish. Following the most southerly drill hole, and in advance of assay results, the Company chose to reiterate that further licence applications to the South are awaiting approval. I suspect once the Creswick results are released there will be a whole new vibe about this BB.

From the July Creswick update "A total of 6 drillholes have been completed to date on the Creswick gold project. Out of these, assays have been returned from 4 of the holes and each of these contain gold, including the scissor hole (CSD004) that was drilled in the opposing direction away from the main structural zone to test peripheral structures. In particular two of these show high-grades (CSD001 CSD003). Current drilling activity is focussing on assessing the strike extent of quartz mineralisation associated with a series of shallow historical gold workings along the Dimocks Main Shale trend between sites CSD001-CSD002 and CSD003-004. There is a strike length of 900m between these two initial drill sites that has not been drilled before. The Directors believe Mercator Gold Australia (MGA) is the first company in history to undertake such mineral exploration in this region to such a high level, and plans are underway to cover the shallow, up-dip extensions of drilled quartz reefs by soil geochemistry.

Results are pending for recently drilled CJD001, which is our most southerly drilled hole along strike to date (2km south of CSD001-CSD002). Significant quartz veining has been intersected within this hole.

Visual evidence of the limited extent of hard-rock gold workings and the mapped extent of eroded alluvial gold workings leading up to the Dimocks Main Shale area provide a practical demonstration to show the potential strike length of this gold system (see announcement 25 September 2018 - https://www.investegate.co.uk/ecr-minerals-plc--ecr-/bus/exploration-mapping-reveals-large-gold-system---creswick-australia/20180925090000Z6056/). Furthermore, as announced on 23 March 2021 (https://www.investegate.co.uk/ecr-minerals-plc/bus/annual-financial-report/20210323132000Z3358/), MGA has applied for additional licenses EL006713 and EL006907 on the southern extension of this vein system to the south."

Two related pre-submitted q & a's re Oral Health for those who missed the presentation and do not have the link

Q4: In April, a one year research and development programme in oral health with the University of Manchester was announced, can you provide any update on the progress made so far please?

The programme is running to schedule and will complete at end July 2022. It is progressing well and all milestones to date have been reached.

Q7: How is the research going for the oral healthcare product? What are you expecting from this effort, in particular target market and product types, B2B or B2C?

Project is running to plan and all milestones have been achieved thus far. The end goal is to prove that a lysate is capable of enhancing the oral microbiome to prevent gum disease etc. The end product would be used in a toothpaste or a mouthwash. We would seek a B2B deal with a licence to own-label in the B2C space (much like the Croda deal)

Note the advert at the bottom of the page

https://www.psoriasis.org/about-us/

Most telling comment for me was that the US pre-registered interest now far outweighs the British numbers which shows that the targeted marketing has done its job

Taken from today's Essentra RNS, North America elective surgeries recovering in Q4

"The Packaging division's revenue declined 6.1% on a LFL basis in Q3 2021 (reported growth of +3.6%, LFL decline of 15.2% vs. 2019) as prescriptions and elective surgery volumes continue to be impacted by the pandemic. The division implemented pricing actions in Q3. The slower than expected recovery in volumes coupled with global supply chain challenges - the availability and cost of raw materials and labour especially in the US, means the Q4 margin is now expected to be slightly below 8%. However, we expect global healthcare systems will continue to recover given pent-up demand, a trend we are already seeing reflected in our current order levels, especially in North America. "

Lol going to have to give up typing on my kindle but you get the gist

Elri did not wish to imply there would be no further improvement beyond 56 days just referencing the Bright Study results analysis that showed at least 56 discredited to show benefit across all categories measured

Yes, researcher it is a fact known to lth's for rather a long time. To demonstrate just how undervalued Opti is, th e23% holding in skin at today's price is £23.94M, which means the value assigned to slimbiome. lpldl, wellbiome and the second generation products, sweetbiotix (which pre-launch already attracts annual 6 figure royalties), and the microbiome modulators, is just £20.03M at todays £43.97 Market Cap. Is there another company with such low risk to potential high reward around at the moment?

It takes upto 56 days to see the full results of axisbiotix on psoriasis so this offer rather cleverly ensures people stick with the programme long enough to witness the full benefits

Opti partner CII is also exhibiting a product (Magic Cluster) that contains slimbiome at Supplyside West
https://exhibitor.supplysidewest.com/ssw21/public/eBooth.aspx?IndexInList=53&FromPage=Exhibitors.aspx&ParentBoothID=&ListByBooth=true&BoothID=111546

https://ciifoods.com/our-products/

Certainly get the feeling that rather than wait for the hole 9 assay results to soften any blow, the intention was to get all the poor results out to the market shortly before maximising the impact of good news to follow from hole 9 and Creswick

The timing of the Health Canada licence award alongside the best weight management product in the USA (Nutrition Industry Executive Award 2021) is excellent. This should really accelerate the prebiotics sales in the American market and encourage Agropur to market slimbiome quite aggressively.

Opti owns 23% of skinbio last time I checked )36,138,569 out of 156,780,236 shares in issue)

Nice find mol; now if you could just find a flyer for the event that features sweetbiotix and it would really make my day

As have a number of firms post covid. Croda sales will have been impacted when cosmetics became superfluous during lockdown and mask wearing

Zero I expect. The Croda price fell post the ex dividend date and is now recovering back to the same sort of levels it reached prior to the dividend payment.